GTBP GT Biopharma Corp: Market Capitalization to Book Value Ratio

GT Biopharma, Inc. (GTBP) strives for leadership in myeloid leukemia therapy by activating the patient's NK cells. Business protection is based on patents and clinical survival rates, while the binary risks of a narrow pipeline are minimized through partnerships. The current price-to-book multiple trend demonstrates asset valuation volatility, while 2.81 reflects the metric's baseline level.

GT Biopharma, Inc. (GTBP) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

GTBP (GT Biopharma Inc): analytical breakdowns and indicator data

- price and consensus price forecast:

Price Chart GT Biopharma, Inc.|GTBP - Forecast Levels Chart

- market capitalization data:

Market Capitalization GT Biopharma Corp|GTBP - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share GT Biopharma|GTBP - Book Capitalization|Market Value to Book Value Ratio gtbiopharma.com|GTBP - Total Business Assets

- debt and liquidity data:

Total Debt to Capital GT Biopharma, Inc.|GTBP - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital GT Biopharma Corp|GTBP - Company Cumulative Debt|Debt to Book Capitalization Ratio GT Biopharma Corp|GTBP - Company Long-Term Loans and Borrowings|Company Current Liabilities GT Biopharma

Fundamental valuation:GTBP (GT Biopharma, Inc.)

The mvsbcap_co ratio determines the market value premium over the company's real net assets. By analyzing the current market-to-book value ratio, an investor assesses the extent to which the price is inflated relative to capital. This metric reveals the speculative gap between the exchange rate and the book value. For GT Biopharma, Inc. (GTBP), such a premium reflects market expectations for the commercial success of the TriKE platform. The potential of the blood cancer therapy is priced into the shares in an anticipatory manner.

Main competitors